AzTrials
AzTrials

Acute Kidney InjuryVINKONCT07643597

Volume Removal Intolerance During Net Ultrafiltration in Acute Kidney Injury Patients

An observational study of Acute Kidney Injury and Fluid Overload, run by Hospital Las Higueras at 10 sites in 7 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record

Search all trials

Trial summary

Acute kidney injury (AKI) is common in critically ill patients and is frequently associated with fluid overload, which can worsen clinical outcomes. Continuous renal replacement therapy (CRRT) allows fluid removal through net ultrafiltration (UFNET), but some patients develop hemodynamic instability or signs of poor… Read more about this study

Who is it for?
Ages 18 years and older
How many people
128 participants
Where
10 sitesin 7 countries
Study dates
6 Jul 2026to 1 Dec 2027
Phase
Observational

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Adult critically ill patients admitted to participating intensive care units with acute kidney injury requiring continuous renal replacement therapy and prescribed net ultrafiltration as part of routine clinical care.

Who may be able to join

  • Age ≥18 years
  • Admission to an Intensive Care Unit
  • Acute kidney injury according to KDIGO criteria
  • Prescription of continuous renal replacement therapy (CRRT) with net ultrafiltration
  • Clinical stability considered sufficient to initiate net ultrafiltration according to the treating clinical team

Who cannot join

  • Chronic kidney replacement therapy prior to ICU admission
  • Pregnancy
  • Limitation of therapeutic effort or goals-of-care decisions at admission or during the observation period
  • Inability to perform hemodynamic or perfusion assessment
  • Extracorporeal membrane oxygenation (ECMO)
  • Refusal to participate in the study

Trial locations and contacts

10 sites in 7 countries. Contact the study team or a site near you to ask about taking part.

Gonzalo Ramírez-Guerrero, MD contact

+56981746173

ramirezguerrero.g@gmail.com

Cristian Pedreros-Rosales, MD contact

cpedreros@me.com

10 sites in 7 countries

Chile4 sites, 4 recruiting
  • Hospital Clínico Regional de Concepción

    Concepción

    Marcos Hernandez, MD, +56976685604, md.hernandezdiaz@gmail.com

    Not yet recruiting
  • Complejo Asistencial Dr. Victor Ríos Ruiz

    Los Ángeles

    Carolina Carrasco, MD, +56975583888, carolina.carrascoa@gmail.com

    Not yet recruiting
  • Hospital Clínico Dra. Eloísa Díaz Insunza de La Florida

    Santiago

    Eduardo Chinchón, MD, +56994514773, doctorchinchon@gmail.com

    Not yet recruiting
  • Hospital Las Higueras de Talcahuano

    Talcahuano

    Gonzalo Ramírez-Guerrero, MD, +56981746173, ramirezguerrero.g@gmail.com

    Cristian Pedreros-Rosales, MD, cpedreros@me.com

    Recruiting

Other trials in Chile

Brazil1 site, 1 recruiting
  • Hospital Cárdio Pulmonar

    Salvador

    Maria Gabriela Guimarães, MD, +5571982121211, Gabrielaguimar@hotmail.com

    Not yet recruiting

Other trials in Brazil

Colombia1 site, 1 recruiting
  • Hospital Universitario San José de Popayán

    Popayán

    David Ballesteros, MD, +573105542506, david.ballesteros.c@gmail.com

    Recruiting

Other trials in Colombia

Ecuador1 site, 1 recruiting
  • Hospital General Enrique Garces

    Quito

    Darío Jiménez, MD, +593992773176, dxjimenezmd@gmail.com

    Not yet recruiting

Other trials in Ecuador

Italy1 site, 1 recruiting
  • Ospedale San Bortolo

    Vicenza

    Matteo Marcello, MD, +393925743247, matteo.marcello92@gmail.com

    Not yet recruiting

Other trials in Italy

Mexico1 site, 1 recruiting
  • Hospital General de Mexico

    Mexico City

    Pablo Galindo, MD, +525551564682, drgalindo@nefrologoscdmx.com

    Sandra Ávila, MD, +524778808890, sandrapav@hotmail.es

    Recruiting

Other trials in Mexico

Peru1 site, 1 recruiting
  • Hospital Nacional Cayetano Heredia

    Lima

    Raúl Valenzuela, MD, +51999308278, raul.valenzuela.cordova@gmail.com

    Not yet recruiting

Other trials in Peru

About this study

Acute kidney injury (AKI) is common in critically ill patients and is frequently associated with fluid overload, which can worsen clinical outcomes. Continuous renal replacement therapy (CRRT) allows fluid removal through net ultrafiltration (UFNET), but some patients develop hemodynamic instability or signs of poor tissue perfusion during this process.

The purpose of this prospective observational study is to evaluate tolerance to net ultrafiltration in critically ill patients with AKI receiving CRRT. The study will assess clinical, hemodynamic, ultrasound, perfusion, and biochemical parameters before and during fluid removal to identify factors associated with ultrafiltration intolerance.

The investigators hypothesize that alterations in hemodynamic, perfusion, and congestion-related parameters can identify patients at increased risk of ultrafiltration intolerance before the development of overt hypotension. The results may help improve individualized fluid removal strategies and optimize the safety of CRRT in critically ill patients.

Read the detailed description

Fluid overload is a frequent and clinically relevant complication in critically ill patients with acute kidney injury (AKI). In this setting, continuous renal replacement therapy (CRRT) is frequently used not only for solute control but also as a strategy for controlled fluid removal through net ultrafiltration (UFNET). Although UFNET is central to de-resuscitation, the individual tolerance to fluid removal is highly variable and is not fully captured by blood pressure monitoring alone.

The concept of ultrafiltration intolerance remains poorly standardized. In clinical practice, intolerance is often recognized only after overt hemodynamic instability occurs, such as hypotension, escalation of vasoactive support, or interruption of fluid removal. However, reductions in cardiac output, impaired tissue perfusion, or worsening venous congestion may precede overt hypotension. Therefore, a multiparametric assessment may allow earlier identification of patients at risk.

This is a prospective, observational, analytical study in critically ill adult patients with AKI receiving CRRT with prescribed UFNET. The study does not assign or modify therapeutic interventions. CRRT modality, anticoagulation strategy, UFNET prescription, vasopressor management, fluid administration, and all other clinical decisions will remain under the responsibility of the treating clinical team according to routine care.

The study will characterize the physiological response to UFNET using a structured multiparametric monitoring approach. Recorded domains will include conventional macrohemodynamic variables, vasoactive support, selected advanced hemodynamic variables when available, focused cardiac ultrasound, venous congestion assessment, peripheral perfusion parameters, fluid balance variables, and selected biochemical markers. Functional hemodynamic maneuvers may be performed when feasible and clinically safe.

Data will be collected prospectively using a standardized case report form. Variables will be recorded at predefined time points before and during the early phase of UFNET, with additional off-schedule recordings if clinical signs compatible with intolerance occur. Source data will be obtained from the electronic or paper medical record, bedside monitoring systems, CRRT prescription and treatment records, laboratory results, and ultrasound assessments performed as part of clinical evaluation.

A data dictionary will define each variable, including its source, units, coding, and expected physiological range when applicable. Data quality procedures will include review of completeness, range checks, consistency checks between related variables, and verification of clinically implausible values against source records. The research team will periodically review entered data to identify missing, inconsistent, or out-of-range values.

Data will be anonymized before analysis. No directly identifiable patient information will be stored in the final analytical database. Access to the study database will be restricted to authorized study investigators. Data will be stored using password-protected institutional or investigator-controlled systems according to local confidentiality and ethical requirements.

The planned sample size is 128 participants, including an estimated analytical sample of 116 participants and an approximate 10% over-recruitment to account for incomplete data, missing assessments, or inability to definitively adjudicate the outcome. The sample size was based on an analytical case-control approach aimed at identifying factors associated with ultrafiltration intolerance.

Missing data will be evaluated before statistical analysis. Variables with substantial missingness may be excluded from inferential analyses. For variables with acceptable levels of missingness, available-case analysis will be performed. The extent and pattern of missing data will be reported.

Statistical analysis will include descriptive statistics, comparison between patients who develop ultrafiltration intolerance and those who do not, and exploratory modeling to identify factors independently associated with intolerance. Continuous variables will be summarized using median and interquartile range or mean and standard deviation, as appropriate. Categorical variables will be summarized as frequencies and percentages. Group comparisons will be performed using appropriate parametric or non-parametric tests according to data distribution. Multivariable logistic regression may be used to explore independent predictors, with covariate selection based on clinical relevance and number of events.

The overall objective of this study is to improve the characterization of ultrafiltration intolerance during CRRT and to generate evidence that may support individualized, physiology-guided fluid removal strategies in critically ill patients with AKI.

Keywords
Net Ultrafiltration, Continuous Renal Replacement Therapy, Fluid Removal, Ultrafiltration Intolerance, Tissue Hypoperfusion, Fluid Overload, VExUS, Point-of-Care Ultrasound
Medical subject headings
Acute Kidney Injury, Edema, Critical Illness

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07643597
Study groupRoleWhat they receive
AKI Patients Receiving CRRT With Net UltrafiltrationAdult critically ill patients with acute kidney injury receiving continuous renal replacement therapy with prescribed net ultrafiltration. Participants will be prospectively evaluated using a multiparametric monitoring strategy including clinical, hemodynamic, ultrasound, perfusion, and biochemical assessments. Patients will subsequently be classified according to the development or absence of ultrafiltration intolerance during the observation period.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Development of Ultrafiltration Intolerance

    Proportion of patients who develop ultrafiltration intolerance according to the protocol-defined composite criteria, including hypotension, increased vasopressor requirements, worsening peripheral perfusion, tissue hypoperfusion, or reduction/interruption of ultrafiltration due to instability.

    Measured: From UFNET initiation (T0) to 24 hours after initiation of net ultrafiltration

Secondary outcomes (11)
  1. Incidence of Ultrafiltration Intolerance

    Percentage of participants who develop ultrafiltration intolerance during the observation period.

    Measured: From UFNET initiation (T0) to 24 hours.

  2. Net Ultrafiltration Rate (mL/kg/h)

    Prescribed and achieved net ultrafiltration rate during continuous renal replacement therapy.

    Measured: From UFNET initiation (T0) to 24 hours.

  3. Time to First Ultrafiltration Intolerance Event (hours)

    Time from UFNET initiation to the first occurrence of ultrafiltration intolerance.

    Measured: From UFNET initiation to 24 hours.

  4. Severity Category of Ultrafiltration Intolerance

    Proportion of participants classified as having mild, moderate, or severe ultrafiltration intolerance according to protocol-defined criteria. Higher categories indicate greater severity of intolerance.

    Measured: From UFNET initiation to 24 hours.

  5. Agreement Between Hypotension-Based and Hypoperfusion-Based Definitions of Ultrafiltration Intolerance

    Agreement between intolerance defined by hypotension criteria and intolerance defined by tissue hypoperfusion criteria, assessed using Cohen's kappa coefficient.

    Measured: From UFNET initiation to 24 hours.

  6. Cumulative Fluid Balance (mL)

    Cumulative fluid balance achieved during the first 24 hours following UFNET initiation.

    Measured: 24 hours after UFNET initiation

  7. Achieved Net Ultrafiltration Volume (mL)

    Total net ultrafiltration volume achieved during the observation period.

    Measured: 24 hours after UFNET initiation

  8. Proportion of Participants Achieving Renal Recovery

    Percentage of participants who recover kidney function sufficiently to discontinue kidney replacement therapy according to the treating clinical team.

    Measured: Up to 90 days after UFNET initiation

  9. Ventilator-Free Days

    Number of days alive and free from invasive mechanical ventilation.

    Measured: Up to 28 days after UFNET initiation

  10. Intensive Care Unit Mortality

    Percentage of participants who die during intensive care unit admission.

    Measured: From UFNET initiation up to 90 days or ICU discharge, whichever occurs first

  11. Hospital Mortality

    Percentage of participants who die during hospital admission.

    Measured: From UFNET initiation until hospital discharge, assessed up to 180 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Jun 2026
  2. Study start6 Jul 2026
  3. Primary completion1 Dec 2027 (estimated)
  4. Study completion1 Dec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
128 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07643597
Sponsor's protocol ID
CEC-SST-15-2026
Acronym
VINKO
Status last verified
Jul 2026
First submitted
1 Jun 2026
Last updated
8 Jul 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: The investigators have not yet determined whether individual participant data (IPD) will be shared. Any future decision regarding data sharing will be made in accordance with institutional policies, ethical approvals, participant confidentiality requirements, and applicable regulations.

Publications

  • Ruste M, Delas Q, Fellahi JL, Jacquet-Lagreze M. Perfusion variables and hemodynamic phenotypes during fluid removal via net ultrafiltration in continuous renal replacement therapy: a retrospective single-center cohort study. J Crit Care. 2026 Feb;91:155310. doi: 10.1016/j.jcrc.2025.155310. Epub 2025 Oct 15.

    PubMed 41101138
  • Bige N, Lavillegrand JR, Dang J, Attias P, Deryckere S, Joffre J, Dubee V, Preda G, Dumas G, Hariri G, Pichereau C, Baudel JL, Guidet B, Maury E, Boelle PY, Ait-Oufella H. Bedside prediction of intradialytic hemodynamic instability in critically ill patients: the SOCRATE study. Ann Intensive Care. 2020 Apr 22;10(1):47. doi: 10.1186/s13613-020-00663-x.

    PubMed 32323060
  • Wong A, Olusanya O, Watchorn J, Bramham K, Hutchings S. Utility of the Venous Excess Ultrasound (VEXUS) score to track dynamic change in volume status in patients undergoing fluid removal during haemodialysis - the ACUVEX study. Ultrasound J. 2024 Mar 27;16(1):23. doi: 10.1186/s13089-024-00370-9.

    PubMed 38538806
  • da Hora Passos R, Caldas JR, Ramos JGR, Dos Santos Galvao de Melo EB, Silveira MAD, Batista PBP. Prediction of hemodynamic tolerance of intermittent hemodialysis in critically ill patients: a cohort study. Sci Rep. 2021 Dec 8;11(1):23610. doi: 10.1038/s41598-021-03110-4.

    PubMed 34880359
  • Douvris A, Zeid K, Hiremath S, Bagshaw SM, Wald R, Beaubien-Souligny W, Kong J, Ronco C, Clark EG. Mechanisms for hemodynamic instability related to renal replacement therapy: a narrative review. Intensive Care Med. 2019 Oct;45(10):1333-1346. doi: 10.1007/s00134-019-05707-w. Epub 2019 Aug 12.

    PubMed 31407042
  • Ruste M, Sghaier R, Chesnel D, Didier L, Fellahi JL, Jacquet-Lagreze M. Perfusion-based deresuscitation during continuous renal replacement therapy: A before-after pilot study (The early dry Cohort). J Crit Care. 2022 Dec;72:154169. doi: 10.1016/j.jcrc.2022.154169. Epub 2022 Oct 3.

    PubMed 36201978
  • Bitker L, Dupuis C, Pradat P, Deniel G, Klouche K, Mezidi M, Chauvelot L, Yonis H, Baboi L, Illinger J, Souweine B, Richard JC. Fluid balance neutralization secured by hemodynamic monitoring versus protocolized standard of care in patients with acute circulatory failure requiring continuous renal replacement therapy: results of the GO NEUTRAL randomized controlled trial. Intensive Care Med. 2024 Dec;50(12):2061-2072. doi: 10.1007/s00134-024-07676-1. Epub 2024 Oct 17.

    PubMed 39417870
  • Ramirez-Guerrero G, Ronco C, Rosner M. Ultrafiltration Tolerance and Improving Outcomes with Continuous Renal Replacement Therapies. Clin J Am Soc Nephrol. 2025 Mar 1;20(3):462-464. doi: 10.2215/CJN.0000000650. Epub 2024 Dec 26. No abstract available.

    PubMed 39724028
  • Ramirez-Guerrero G, Ronco C. Ultrafiltration Tolerance: A Phenotype That We Need to Recognize. Blood Purif. 2024;53(7):541-547. doi: 10.1159/000537941. Epub 2024 Feb 20.

    PubMed 38377967
  • Melo P, Ramirez-Guerrero G, Castro R, Wong A, Argaiz ER, Ostermann M, Hernandez G, Kattan E. Ultrafiltration in the critically ill patient: a framework for personalized care. Crit Care. 2026 Jan 24;30(1):87. doi: 10.1186/s13054-026-05836-x.

    PubMed 41580864
  • Ramirez-Guerrero G, Pedreros-Rosales C, Galindo P, Ulloa R, Alarcon J, Avila S, Kattan E, Melo P, Ballesteros D, Valenzuela R, Guimaraes G, Ferrada R, Pfeifer C, Villalobos V, Mas G, Marcello M, Klinkmann G, Ronco C. Volume removal intolerance during net ultrafiltration in patients with acute kidney injury in the intensive care unit: protocol for a prospective multicentre observational study (VINKO). BMJ Open. 2026 Sep 15;16(9):e125067. doi: 10.1136/bmjopen-2026-125067.

    PubMed 42744368

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in